SynthesisNeurosurgical review2026
Safety and efficacy of flow diversion for blood blister aneurysms: A comprehensive systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood blister aneurysms (BBAs) are surgically challenging with a high risk of bleeding and recurrence. Endovascular techniques, particularly flow diverters (FDs), offer a less invasive alternative to open surgery and conventional endovascular techniques by endovascular reconstruction and reducing aneurysm sac manipulation. This review aims to evaluate the safety and efficacy of FDs in treating BBAs, considering factors affecting outcomes. A systematic review of PubMed, Scopus, and Embase was performed aiming at studies reporting outcomes of FDs for BBAs. All reported radiologic, clinical, and complication outcomes were meta-analytically pooled. A total of 39 studies including 511 patients with BBAs treated with FDs were identified. The average patient age was 50.55 years, with 65.99% female, and 83.12% of aneurysms located in the internal carotid artery. Most aneurysms had ruptured before treatment, with an average maximum diameter of 2.94 mm. The mean time from symptom onset to FD treatment was 5.44 days, with Pipeline Embolization Devices used most frequently. The overall complete aneurysm occlusion rate was 87.56%, and 84.05% of patients had a good neurological outcome (mRS ≤ 2). In the subgroup analysis of large multicentric studies, the complete occlusion and good neurological outcome rates were 87.14% and 81.95%, respectively. Complications included intra-operative rupture (1.60%), hemorrhagic (5.62%), thromboembolic (6.89%), and neurologic (6.30%) complications, with a mortality rate of 6.55%. Older age and higher subarachnoid hemorrhage grades were associated with worse outcomes following flow diversion. This review demonstrates that FDs are safe and effective for treating ruptured BBAs, achieving promising rates of complete aneurysm occlusion and favorable neurological outcomes. However, complications such as intra-operative rupture and thromboembolic events still persist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.